Sanofi and Teva Pharmaceuticals have reported that the Phase IIb RELIEVE UCCD study of the human IgG1-λ2 monoclonal antibody ...

The search for effective therapies in ulcerative colitis, a chronic inflammatory condition affecting the colon and rectum ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

overseeing more than 30 oncology programs spanning IND filings through Phase 1/2, including the recently approved IMDELLTRA™ (TARLATAMAB-DLLE) a first-in-class DLL3-targeted bispecific T-cell ...

Amgen’s AMGN stock has declined 12.1% in the past month. Late last month, Amgen announced the much-awaited 52-week top-line data from a phase II study on MariTide, its GLP-1 therapy being ...

This would be similar to other T-cell engagers being explored in solid tumors, such as tarlatamab for small ... Enrollment in the phase 1 study for this molecule is ongoing. As of their latest ...

We're nearing the end of Phase 5 of the MCU which marks the midway point of The Multiverse Saga, following the releases of Agatha All Along and Deadpool & Wolverine. If that all sounds confusing ...

Results phase 3 LIBRETTO-431 trial presented at the 2023 ESMO Congress ... for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. Tarlatamab 10 mg showed responses in patients ...